China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
The current ruling will assure the safety of the use of Ranitidine for Indian patients
This one-of-a-kind ophthalmic subspecialty division is focused on the treatment of the eye condition glaucoma
Move to increase affordability and accessibility for heart failure patients across the country
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Subscribe To Our Newsletter & Stay Updated
